Assess whether working capital should be a walk-away from regulatory-approval
August 31, 2026
SITUATION After an earnout based on 'adjusted EBITDA' with no dictionary, regulatory-approval critical-path calendar is what environmental diligence manager can touch in a health-system acquiring a specialty practice. M&A Due Diligence will live with Proceed versus Reprice on this Earnings and Revenue Quality file.
DECISION Environmental diligence manager in a health-system acquiring a specialty practice must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after an earnout based on 'adjusted EBITDA' with no dictionary.
HYPOTHESES TO TEST 1. The population in regulatory-approval critical-path calendar is the one an earnout based on 'adjusted EBITDA' with no dictionary named, so Proceed follows for this Earnings and Revenue Quality file. 2. The population in regulatory-approval critical-path calendar is adjacent only to an earnout based on 'adjusted EBITDA' with no dictionary; Reprice is the honest M&A Due Diligence call. 3. A health-system acquiring a specialty practice already contained an earnout based on 'adjusted EBITDA' with no dictionary before regulatory-approval critical-path calendar arrived; no new Earnings and Revenue Quality path. 4. Provenance on regulatory-approval critical-path calendar after an earnout based on 'adjusted EBITDA' with no dictionary is broken; do not pick Proceed or Reprice yet.
ANALYSIS REQUIRED 1. Test whether an earnout based on 'adjusted EBITDA' with no dictionary is a diligence gap, a price chip, or a walk-away. 2. Separate a one-off add-back from a recurring earnings issue in regulatory-approval critical-path calendar. 3. Map reps, earnout mechanics, and integration risk a health-system acquiring a specialty practice would inherit. 4. For this M&A Due Diligence Earnings and Revenue Quality file, read regulatory-approval critical-path calendar against an earnout based on 'adjusted EBITDA' with no dictionary and write the one fact that would move working capital should be for environmental diligence manager.
RECOMMENDATION Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Earnings and Revenue Quality packet (regulatory-approval critical-path calendar after an earnout based on 'adjusted EBITDA' with no dictionary). The follow-on Earnings and Revenue Quality action is what environmental diligence manager does next: implement the option, assign an owner, and log the missing fact.
COMMAND RETURNS - Bottom-line M&A Due Diligence option on working capital should be, then the evidence in regulatory-approval critical-path calendar, then the action for environmental diligence manager - Hypothesis scorecard against regulatory-approval critical-path calendar: supported / rejected / untestable - What changes working capital should be if an earnout based on 'adjusted EBITDA' with no dictionary is later withdrawn - Named option among Proceed, Reprice, Walk and the fact that kills the others
Explore more
More M&A Due Diligence prompts
- Assess whether the carve-out is operable on day one from regulatory-approval
- Assess whether environmental liability is capped or open-ended (570f5a)
- Assess whether regulatory approval is a timing risk or a deal risk (b975ff)
- Whether to re-trade, restructure, or drop from carve-out stranded-cost model
- Assess whether to re-trade, restructure, or drop from regulatory-approval
Explore related decision areas
See governed multi-model AI on your own prompt
Compare GPT-5, Claude, and Gemini side by side, with human review and a decision record built in.

